Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition
Sign Up to like & getrecommendations! Published in 2020 at "Drug Delivery and Translational Research"
DOI: 10.1007/s13346-020-00839-9
Abstract: Linagliptin (LGP), a novel anti-diabetic drug, is a DPP-4 inhibitor used in the treatment of type II diabetes. One of the major disadvantages of LGP is its low oral bioavailability (29.5%) due to first-pass metabolism… read more here.
Keywords: oral bioavailability; bioavailability; lipid nanoparticles; lgp slns ... See more keywords